Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)
This scheme of doxorubicin, dacarbazine, and nivolumab is feasible and well tolerated. Clinical activity is encouraging and the prognostic impact of HMGB1 supports the relevance of ICD activation. Further clinical research is already underway with this concept in leiomyosarcoma.
Authors
- Robert Díaz Beveridge (ORCID: https://orcid.org/0000-0003-3719-7014)
- Ana Sebio (ORCID: https://orcid.org/0000-0003-3333-2370)
- Antonio M. Gutierrez (ORCID: https://orcid.org/0000-0001-9062-077X)
- Claudia Valverde (ORCID: https://orcid.org/0000-0003-4107-8616)
- David S. Moura (ORCID: https://orcid.org/0000-0002-6514-2419)
- Nadia Hindi (ORCID: https://orcid.org/0000-0002-5864-762X)
- Javier Martínez‐Trufero (ORCID: https://orcid.org/0000-0002-0997-2573)
- Javier Martín‐Broto (ORCID: https://orcid.org/0000-0001-7350-6916)
- Javier Fernández-Jara (ORCID: https://orcid.org/0000-0003-3546-6356)
- Enrique González‐Billalabeitia (ORCID: https://orcid.org/0000-0003-3143-3143)
- Rafael Ramos
- Josefina Cruz
- Laura Hernández-Vargas (ORCID: https://orcid.org/0000-0002-2699-8580)
- Irene Carrasco
Institutions
- Hospital Universitario de Canarias (ES)
- Hospital de Sant Pau (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Hospital Universitario Rey Juan Carlos (ES)
- Hospital Universitario 12 De Octubre (ES)
- Hospital Universitario Miguel Servet (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Hospital Universitario Son Espases (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1200/jco.24.00358
- Citations
- 18
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 5.09